Cargando…
MicroRNA-185 and 342 Inhibit Tumorigenicity and Induce Apoptosis through Blockade of the SREBP Metabolic Pathway in Prostate Cancer Cells
MicroRNA (miRNA or miR) inhibition of oncogenic related pathways has been shown to be a promising therapeutic approach for cancer. Aberrant lipid and cholesterol metabolism is involved in prostate cancer development and progression to end-stage disease. We recently demonstrated that a key transcript...
Autores principales: | Li, Xiangyan, Chen, Yi-Ting, Josson, Sajni, Mukhopadhyay, Nishit K., Kim, Jayoung, Freeman, Michael R., Huang, Wen-Chin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739799/ https://www.ncbi.nlm.nih.gov/pubmed/23951060 http://dx.doi.org/10.1371/journal.pone.0070987 |
Ejemplares similares
-
miR-17* Suppresses Tumorigenicity of Prostate Cancer by Inhibiting Mitochondrial Antioxidant Enzymes
por: Xu, Yong, et al.
Publicado: (2010) -
Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations
por: Li, Xiangyan, et al.
Publicado: (2015) -
SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer
por: Li, Xiangyan, et al.
Publicado: (2016) -
Targeting the tumor-stromal-immune cell axis
por: Gururajan, Murali, et al.
Publicado: (2015) -
β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy
por: Nomura, Takeo, et al.
Publicado: (2014)